US4409205A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Ophthalmic solution
Assignee: Iolab Corp
•
Filing: 1981-01-16
•
Granted: 1983-10-11
•
Expires: 2001-01-16
Abstract
Abstract An ophthalmic aqueous solution having an ionic salt ion content within the range 0.01% to 7.5% expressed as sodium chloride equivalents and comprising a non-ionic synthetic polymer such as polyvinyl alcohol and/or polyethylene glycol, and a non-ionic tonicity adjusting agent. The solution is effective in treating "dry eye" conditions by causing a normalization of irregularly structured tears and at least retarding the precipitation of potein-like substances from the aqueous layers thereof.
Inventors
- 👤 Charles D. Shively
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 23:16
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/74; A61K31/765; A61K31/77; A61K9/00; A61K9/0012; A61K9/0048
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
119 words
An ophthalmic solution for use in normalizing irregularly structured tear films in mammalian eyes having an ionic salt ion content within the range of from about 0.01% to about 0.75% expressed as sodium chloride equivalents, and a viscosity within the range of from about 1 cps to 150 cps at 23° C., comprising an aqueous solution of a water soluble non-ionic synthetic polymer having a molecular weight within the range of from about 300 to about 250,000 and selected from the group consisting of polyvinyl alcohol, polyethylene glycol and mixtures thereof, and from about 0.1 to about 5.0% of a non-ionic tonicity adjusting agent selected from the group consisting of mannitol, sorbitol, dextrose, sucrose, urea, glycerol and mixtures thereof.
Claim 2
Dependent Claim
119 words
An ophthalmic solution for use in normalizing irregularly structured tear films in mammalian eyes having an ionic salt ion content within the range of from about 0.01% to about 0.75% expressed as sodium chloride equivalents, and a viscosity within the range of from about 1 cps to 150 cps at 23° C., comprising an aqueous solution of a water soluble non-ionic synthetic polymer having a molecular weight within the range of from about 300 to about 250,000 and selected from the group consisting of polyvinyl alcohol, polyethylene glycol and mixtures thereof, and from about 0.1 to about 5.0% of a non-ionic tonicity adjusting agent selected from the group consisting of mannitol, sorbitol, dextrose, sucrose, urea, glycerol and mixtures thereof.
Claim 3
Dependent Claim
25 words
An ophthalmic solution according to claim 1 wherein the non-ionic synthetic polymer is polyvinyl alcohol, in an amount of from about 0.1% to about 5.0%.
Claim 4
Dependent Claim
25 words
An ophthalmic solution according to claim 1 wherein the non-ionic synthetic polymer is polyethylene glycol in an amount of from about 0.25% to about 3.5%.
Claim 5
Dependent Claim
17 words
An ophthalmic solution according to claims 1 or 2 or 3 further comprising a viscosity increasing agent.
Claim 6
Dependent Claim
33 words
An ophthalmic solution according to claim 4 wherein said viscosity increasing agent is selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, carboxymethylcellulose, polymeric polyethylene glycols and oxides, and polyoxypropylene-polyoxyethylene block copolymers.
Claim 7
Dependent Claim
25 words
An ophthalmic solution according to claim 5 having a viscosity within the range of from about 10 cps to about 150 cps at 23° C.
Claim 8
Dependent Claim
28 words
An ophthalmic solution according to claim 4 wherein said viscosity building agent is present in solution at a level of from about 0.05% to about 10% by weight.
Claim 9
Dependent Claim
24 words
An ophthalmic solution according to claims 1 or 2 or 3, which is adjusted to a pH of from about 4.5 to about 8.5.
Claim 10
Dependent Claim
31 words
A method of treating an eye condition characterized by abnormally structured tear films comprising topically applying to said eye a pharmacologically effective amount of the ophthalmic solution defined in claim 1.
References Cited (Backward Citations)
US3311577A
Cited
GB1090492A
Cited
US3856919A
Cited
US3843782A
Cited
US3927205A
Cited
US3920810A
Cited
US4003991A
Cited
US4039662A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-10-10 | 1987-04-11 | 1987-10-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-10-10 | 1991-04-11 | 1991-10-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-10-10 | 1995-04-11 | 1995-10-11 | $7700.00 | Window Closed / Lapsed |